Das Bild zeigt rechts ein Trichterglas mit blauer Flüssigkeit und Glasstab zum Umrühren. Daneben steht ein Reagenzglasständer mit Reagenzgläsern, die ebenfalls blaue Flüssigkeit enthalten. Im Hintergrund ist ein Forscher zu sehen, der in der rechten Hand eine Pipette hält.

Biomarker

You are here:

Characterization of biomarkers for the prediction of response to SAHA in B-cell lymphoma

The therapy of aggressive B-cell lymphoma could be significantly improved by the use of the therapeutic CD20 antibody rituximab, but unfortunately approximately 50% of patients can not be treated adequately. Therefore, the search for improved therapies is a primary goal. Previous studies have shown evidence that epigenetic features may be associated with the clinical course of B-cell lymphoma. For this reason, influence of the epigenetic profiles of tumor cells, particularly in combination with standard chemotherapy, can be an alternative therapeutic approach.

SAHA (Vorinostat, Zolinza®) is now approved for the treatment of cutaneous T-cell lymphoma and in individual B-cell lymphoma patients a complete response was observed by SAHA monotherapy. The aim of the project is to identify biomarkers of "companion diagnostics" to identify appropriate B-cell lymphoma patients for the treatment with the histone deacetylase inhibitor SAHA.

Literature

Joosten, M., et al., A novel approach to detect resistance mechanisms reveals FGR as a factormediating HDAC inhibitor SAHA resistance in B-cell lymphoma, Molecular Oncology (2016); PMID: 27324824

Supported by "Zentrales Innovationsprogramm Mittelstand" des Bundesministeriums für Wirtschaft und Technologie (BMWi)